Cryoport Introduces CryoStork Next Flight Out Cryogenic Logistics Solution for the Reproductive Health Market

IRVINE, Calif., March 1, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced the launch of CryoStorkSM Next Flight Out for the reproductive health market. CryoStorkSM Next Flight Out is the fastest, most reliable solution on the market for reproductive health patients, providing express transportation across the United States and the world for reproductive health commodities such as sperm, eggs, embryos and reproductive tissues.

Cryoport, Inc.

Cryoport's qualified and secure next flight out cryogenic logistics solution will greatly benefit reproductive health patients, such as those undergoing in vitro fertilization treatments, other forms of assisted reproductive technology or simply needing to move their valuable assets.  CryoStorkSM answers the growing demand for efficient and dependable logistics services for the reproductive health market.

Cryoport, which currently supports over 400 fertility clinics in the U.S. and other countries, combines a powerful and efficient end-to-end cold chain logistics solution with world class cryogenic logistics technology and a cutting-edge logistics management platform. Cryoport Express® Dry Shippers use liquid nitrogen in dry vapor form to keep reproductive commodities at cryogenic conditions; Cryoport's dependable technology eliminates temperature excursions and risk of embryo, sperm, or egg degradation. Cryoport is the only company to provide clinics with documented Chain- of-Condition and Chain-of-Custody data through its proprietary SmartPak II™ Condition Monitoring system, which provides tracking and monitoring shipments in real time.

Jerrell Shelton, Chief Executive Officer of Cryoport, commented, "Handling irreplaceable biological commodities, such as embryos, eggs and sperm, requires reproductive health clinics and patients to put their utmost trust in Cryoport to provide the most advanced technology available today for reliability. Clients choose Cryoport because our Cryoport Express® Solutions, which allow our client care team to track and monitor not just the progression of the shipments, but also the condition of the shippers at every stage of the journey. We have launched the CryoStorkSM Next Flight Out service to provide an even more efficient and streamlined logistics solution which our clients can trust to safely and securely deliver their irreplaceable biological shipments in a timely manner. With many couples struggling with infertility and approximately 6.7 million women in the U.S. unable to have a child per the American Society for Reproductive Medicine (ASRM), we are proud to provide the CryoStorkSM Next Flight Out solution in support of the reproductive health market. We expect increasing clinic adoption of our services, which will, of course, continue to drive growth."

About Cryoport, Inc.

Cryoport is the life sciences industry's most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

Cryoport is dedicated to

  • simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;
  • delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and
  • providing vital information that provides peace of mind throughout the life of each logistics process.

For more information, visit Sign up to follow @cryoport on Twitter at

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, such as the expected use of the proceeds from the Offer, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2016. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.


To view the original version on PR Newswire, visit:

SOURCE Cryoport, Inc.